Clinical trials: Mild Cognitive Impairment, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Mild Cognitive Impairment
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Dementia, Mild, Mild Cognitive Impairment
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and…
- Conditions
- Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
- Trial name
- NCT07083154
- Testing
- Mazdutide
- Where
- 8 sites in China
- Volunteers
- 420 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Mild Cognitive Impairment, Early Alzheimer's Disease
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional…
- Conditions
- Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
- Trial name
- NCT07512362
- Testing
- human Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bernard (Barry) Baumel
Alzheimer Disease
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory…
- Trial name
- NCT05999084
- Testing
- Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 735 people
- Sponsor
- Emory University
Dementia, Parkinsonism
DaTSCAN Imaging in Aging and Neurodegenerative Disease
The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other…
- Conditions
- Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
- Trial name
- NCT01453127
- Testing
- I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Mayo Clinic
Mild Cognitive Impairment
Observation of Inhalation of CXMCI-01 Essential Oil on Patients With Mild Cognitive Impairment
Memory declined and cognitive impairment are common complaints in neurology clinics. Before diagnosing as dementia, individuals will undergo a transition period, including mild cognitive impairment (MCI).
- Trial name
- CXMCI-01-MCI (NCT06902181)
- Testing
- Experimental Group - 100% CXMCI-01 Essential Oil
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- China Medical University Hospital
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Alzheimer Disease
F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)
The purpose of this research study is to evaluate a new radioactive compound used in positron emission tomography (PET) scans in identifying tau tangles (a certain protein that might be associated with Dominantly Inherited…
- Trial name
- AV ADAD (NCT02414178)
- Testing
- F 18 T807
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Washington University School of Medicine
Alzheimer Disease
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease.
- Trial name
- ADVISe (NCT04576793)
- Testing
- 11C-ER176, 18F-MK6240, 18F-Florbetaben
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Columbia University
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
- Trial name
- NCT07422857
- Testing
- [18F]-APN-1607
- Where
- 2 sites in China
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Gait Apraxia, Mild Cognitive Impairment
Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study
Motor slowing and cognitive slowing are more prevalent as we age. Importantly, the presence of both in an older person increases their risk of having dementia by ten times.
- Conditions
- Gait Apraxia, Mild Cognitive Impairment, Subjective Cognitive Impairment, Cerebral Atrophy
- Trial name
- NCT03020381
- Where
- Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Manuel Montero Odasso
Alzheimer Disease (AD), Alzheimer Dementia
Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research
Preliminary clinical trial results indicate that Aβ-targeting monoclonal antibody drugs can delay disease progression more effectively.
- Conditions
- Alzheimer Disease (AD), Alzheimer Dementia, Mild Cognitive Impairment (MCI)
- Trial name
- NCT07152418
- Testing
- Lecanemab 10 mg/kg, Conventional anti-dementia treatment group
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cognitive Dysfunction, Lewy Body Disease
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily…
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Trial name
- NCT07589595
- Testing
- Donanemab
- Where
- 72 sites in United States, Japan and 2 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Mild Cognitive Impairment
BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers
This research study aims to examine biomarkers of Alzheimer's disease as early as possible which could potentially be a screening tool for the general population.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT05457998
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Butler Hospital
Mild Cognitive Impairment, Alzheimer Dementia
Innate Immunity Stimulation Via TLR9 in Early AD
This single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either Mild Cognitive Impairment due to Alzheimer's disease (MCI) or Mild Alzheimer's disease dementia (mild AD).
- Trial name
- NCT05606341
- Testing
- CpG1018
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Alzheimer Disease
A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease
This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer's…
- Trial name
- NCT06619613
- Testing
- Alzheimer Disease (AD)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Keymed Biosciences Co.Ltd
Alzheimer Disease, Mild Cognitive Impairment
The Swedish BioFINDER - Preclinical AD Study
This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT06121544
- Testing
- Plasma tau, Plasma β-Amyloid 42/40 (Aβ42/Aβ40), Flutemetamol F18 Injection
- Where
- Sweden
- Volunteers
- 800 people
- Sponsor
- Skane University Hospital
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to…
- Trial name
- NCT07489599
- Testing
- QLH2405
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Alzheimer s Disease, Mild Cognitive Impairment
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT07169630
- Testing
- 18F-PF974, 18F-florbetaben
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)